Antiplatelet Therapy after Endovascular Intracranial Aneurysm Surgery: Comparative Effectiveness and Safety Insights from Systematic Review and Meta-Analysis
Pharmacology · 16.05.2026 · 1-18
DOI: 10.1159/000552257 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmacology, online erschienen am 16.05.2026. Verfasst von Qiuling Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical…. Hauptthemen laut MEDLINE: Endovascular Procedures, Intracranial Aneurysm, Platelet Aggregation Inhibitors, Thromboembolism. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Introduction
Endovascular treatment of intracranial aneurysms – particularly stent-assisted coiling and flow diversion (FD) – requires antiplatelet (AP) therapy to prevent thromboembolic complications. However, standard fixed-dose regimens may not account for individual variability in drug response or device-specific thrombogenicity. This systematic review and meta-analysis evaluate the comparative effectiveness and safety of tailored AP protocols versus standard regimens.
Methods
A comprehensive search of PubMed, Embase, and Cochrane Library identified 27 eligible studies (n = 8,452 patients) comparing tailored AP strategies – including platelet function testing (PFT)-guided adjustments, potent P2Y12 inhibitors, and surface-modified device protocols – with standard dual AP therapy. Primary outcomes were thromboembolic events and major hemorrhage within 30 days. Meta-analysis was performed using a random-effects model with a 2× scaling factor and 1.0 continuity correction to address zero-event cells (“Khanafer effect”). Subgroup and trial sequential analyses (TSAs) were conducted to assess robustness and certainty.
Results
Tailored AP protocols significantly reduced thromboembolic events (RR 0.45; 95% CI: 0.37–0.54; p < 0.001), with TSA confirming adequate information size. Major hemorrhage was also reduced (RR 0.52; 95% CI: 0.32–0.83; p < 0.05), though heterogeneity was high (I2 = 77.5%). Subgroup analysis revealed the greatest benefit in surface-modified FD using single antiplatelet therapy (SAPT) (RR 0.06 for ischemia; RR 0.11 for hemorrhage). Tailored clopidogrel (PFT-guided) and potent P2Y12 inhibitors (prasugrel/ticagrelor) both demonstrated superior ischemic protection without increasing bleeding risk. Efficacy was consistent across ruptured and unruptured aneurysm cohorts.
Conclusions
Tailored AP therapy significantly improves ischemic outcomes without compromising safety in patients undergoing endovascular aneurysm treatment. Surface-modified devices enabling SAPT offer a promising evolution in neurointerventional care. These findings support a shift from fixed-dose regimens toward personalized protocols informed by platelet biology and device technology. Further large-scale trials are warranted to standardize individualized AP strategies into clinical guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China.
- Department of Cardiology, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China.
- Department of Pharmacy, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China, lhfyljl@163.com.
- Department of Pharmacy, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen, China, m13620924303@163…
Zitieren
APA
Chen, Q., Lin, Y., Liu, C., Jiang, Q., Li, J., & Zhan, H. (2026). Antiplatelet Therapy after Endovascular Intracranial Aneurysm Surgery: Comparative Effectiveness and Safety Insights from Systematic Review and Meta-Analysis. Pharmacology, 1-18. https://doi.org/10.1159/000552257
Vancouver
Chen Q, Lin Y, Liu C, Jiang Q, Li J, Zhan H. Antiplatelet Therapy after Endovascular Intracranial Aneurysm Surgery: Comparative Effectiveness and Safety Insights from Systematic Review and Meta-Analysis. Pharmacology. 2026:1-18. doi:10.1159/000552257
BibTeX
@article{Chen2026,
author = {Chen, Qiuling and Lin, Yaowang and Liu, Cheng and Jiang, Qiuqiong and Li, Jianglin and Zhan, Hui},
title = {Antiplatelet Therapy after Endovascular Intracranial Aneurysm Surgery: Comparative Effectiveness and Safety Insights from Systematic Review and Meta-Analysis},
journal = {Pharmacology},
year = {2026},
pages = {1--18},
doi = {10.1159/000552257}
}
EUVIMED